{"title":"Authors' reply to Kirar et al. and Chaudhuri","authors":"S. Adak, V. Patil, K. Prabhash","doi":"10.4103/crst.crst_81_23","DOIUrl":"https://doi.org/10.4103/crst.crst_81_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"43 1","pages":"159 - 160"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74530856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Authors' reply to Sahu, Salins, and Thota","authors":"Kusum K. Rohilla, C. Kalyani","doi":"10.4103/crst.crst_73_23","DOIUrl":"https://doi.org/10.4103/crst.crst_73_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"49 1","pages":"145 - 146"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79406788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tabitha M. Sabu, V. Noronha, A. Rao, Anita B. Kumar, S. Gattani, A. Ramaswamy, Anupa Pillai, R. Dhekale, R. Castelino, Sharath Kumar, Arshiya Sehgal, P. Rana, V. Gota, R. Badwe, K. Prabhash
Background: Older patients with cancer are at a higher risk of invasive infections. Vaccination is an effective approach to decrease the mortality and morbidity associated with infections. Objectives: Our primary objective was to evaluate the proportion of older patients with cancer who had received routine vaccinations against pneumococcal, influenza, and coronavirus disease 2019 (COVID-19). Our secondary objective was to identify the factors associated with vaccine uptake such as age, sex, education, marital status, comorbidities, and place of residence. Materials and Methods: This cross-sectional observational study was conducted in the geriatric oncology outpatient clinic of the Department of Medical Oncology at the Tata Memorial Hospital, a tertiary care cancer hospital in Mumbai, India, from February 2020 to January 2023. We included all patients aged ≥60 years who were evaluated in the geriatric oncology clinic during the study period and for whom the immunization details were available. The uptake of COVID-19 vaccine was calculated from March 2021 onwards, which was when the COVID-19 vaccine became available to patients aged ≥60 years in India. Results: We enrolled 1762 patients; 1342 (76.2%) were male. The mean age was 68.4 (SD, 5.8) years; 795 (45%) patients were from the west zone of India. Only 12 (0.68%) patients had received the pneumococcal vaccine, and 13 (0.7%) had received the influenza vaccine. At least one dose of the COVID-19 vaccine had been taken by 1302 of 1562 patients (83.3%). On univariate logistic regression, education, marital status, geographic zone of residence, and primary tumor site were correlated with the uptake of COVID-19 vaccine. Factors associated with a greater COVID-19 vaccine uptake included education (up to Std 10 and higher vs. less than Std 10: Odds Ratio [OR], 1.46; 95% confidence interval [CI], 1.07-1.99; P = 0.018, and illiterate vs. less than Std 10: OR, 0.70; 95% CI, 0.50-0.99; P = 0.041), marital status (unmarried vs. married: OR, 0.27; 95% CI, 0.08-1.08; P = 0.046, and widow/widower vs. married: OR, 0.67; 95% CI, 0.48-0.94; P = 0.017), lung and gastrointestinal vs. head-and-neck primary tumors (lung cancer vs. head-and-neck cancer: OR, 1.60; 95% CI, 1.02–2.47; P = 0.038, and gastrointestinal vs .head-and-neck cancer: OR, 2.18; 95% CI, 1.37-3.42; P < 0.001), and place of residence (west zone vs. central India: OR, 0.34; 95% CI, 0.13-0.75; P = 0.015). Conclusion: Fewer than 1 in 100 older Indian patients with cancer receive routine immunization with influenza and pneumococcal vaccines. Hearteningly, the uptake of COVID-19 vaccination in older Indian patients with cancer is over 80%, possibly due to the global recognition of its importance during the pandemic. Similar measures as those used to increase the uptake of COVID-19 vaccines during the pandemic may be beneficial to increase the uptake of routine vaccinations (Clinical Trials Registry, India: CTRI/2020/04/024675).
{"title":"Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study","authors":"Tabitha M. Sabu, V. Noronha, A. Rao, Anita B. Kumar, S. Gattani, A. Ramaswamy, Anupa Pillai, R. Dhekale, R. Castelino, Sharath Kumar, Arshiya Sehgal, P. Rana, V. Gota, R. Badwe, K. Prabhash","doi":"10.4103/crst.crst_29_23","DOIUrl":"https://doi.org/10.4103/crst.crst_29_23","url":null,"abstract":"Background: Older patients with cancer are at a higher risk of invasive infections. Vaccination is an effective approach to decrease the mortality and morbidity associated with infections. Objectives: Our primary objective was to evaluate the proportion of older patients with cancer who had received routine vaccinations against pneumococcal, influenza, and coronavirus disease 2019 (COVID-19). Our secondary objective was to identify the factors associated with vaccine uptake such as age, sex, education, marital status, comorbidities, and place of residence. Materials and Methods: This cross-sectional observational study was conducted in the geriatric oncology outpatient clinic of the Department of Medical Oncology at the Tata Memorial Hospital, a tertiary care cancer hospital in Mumbai, India, from February 2020 to January 2023. We included all patients aged ≥60 years who were evaluated in the geriatric oncology clinic during the study period and for whom the immunization details were available. The uptake of COVID-19 vaccine was calculated from March 2021 onwards, which was when the COVID-19 vaccine became available to patients aged ≥60 years in India. Results: We enrolled 1762 patients; 1342 (76.2%) were male. The mean age was 68.4 (SD, 5.8) years; 795 (45%) patients were from the west zone of India. Only 12 (0.68%) patients had received the pneumococcal vaccine, and 13 (0.7%) had received the influenza vaccine. At least one dose of the COVID-19 vaccine had been taken by 1302 of 1562 patients (83.3%). On univariate logistic regression, education, marital status, geographic zone of residence, and primary tumor site were correlated with the uptake of COVID-19 vaccine. Factors associated with a greater COVID-19 vaccine uptake included education (up to Std 10 and higher vs. less than Std 10: Odds Ratio [OR], 1.46; 95% confidence interval [CI], 1.07-1.99; P = 0.018, and illiterate vs. less than Std 10: OR, 0.70; 95% CI, 0.50-0.99; P = 0.041), marital status (unmarried vs. married: OR, 0.27; 95% CI, 0.08-1.08; P = 0.046, and widow/widower vs. married: OR, 0.67; 95% CI, 0.48-0.94; P = 0.017), lung and gastrointestinal vs. head-and-neck primary tumors (lung cancer vs. head-and-neck cancer: OR, 1.60; 95% CI, 1.02–2.47; P = 0.038, and gastrointestinal vs .head-and-neck cancer: OR, 2.18; 95% CI, 1.37-3.42; P < 0.001), and place of residence (west zone vs. central India: OR, 0.34; 95% CI, 0.13-0.75; P = 0.015). Conclusion: Fewer than 1 in 100 older Indian patients with cancer receive routine immunization with influenza and pneumococcal vaccines. Hearteningly, the uptake of COVID-19 vaccination in older Indian patients with cancer is over 80%, possibly due to the global recognition of its importance during the pandemic. Similar measures as those used to increase the uptake of COVID-19 vaccines during the pandemic may be beneficial to increase the uptake of routine vaccinations (Clinical Trials Registry, India: CTRI/2020/04/024675).","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"40 1","pages":"52 - 61"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80030654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/crst.crst_329_22
S. Biswal, Biplab Sarkar, Tanweer Shahid, Monika Goyal
{"title":"Skin reaction in patients with head-and-neck cancer due to the use of a face mask as COVID-19 protective equipment: A case report","authors":"S. Biswal, Biplab Sarkar, Tanweer Shahid, Monika Goyal","doi":"10.4103/crst.crst_329_22","DOIUrl":"https://doi.org/10.4103/crst.crst_329_22","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"39 1","pages":"124 - 126"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76304827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/crst.crst_139_23
Monika Thakur
Your dreams are filled with fear and dread, As you lay restless in your bed, But know that you are not alone, For in your heart, a light has shone. You are strong, courageous, and true, And we stand with you in all you do, Together we will face this fight, with hope and love, shining bright. So when you feel like giving in, Remember, we are here to win, And though the road may be rough and steep, We’ll hold your hand and never let you weep. For you are not just a cancer patient, But a warrior, a hero, a testament, To the strength of the human spirit, And we’ll stand by you, every minute. So rest now, dear one, and know, That we’ll be with you as you go, Through the valleys and the peaks, with love, hope, and endless streaks. I am fearful, I am anxious, and I may not sleep, but the faith in my fight will never take a leap Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
{"title":"In the still dark night: The unsung pain of cancer patients","authors":"Monika Thakur","doi":"10.4103/crst.crst_139_23","DOIUrl":"https://doi.org/10.4103/crst.crst_139_23","url":null,"abstract":"Your dreams are filled with fear and dread, As you lay restless in your bed, But know that you are not alone, For in your heart, a light has shone. You are strong, courageous, and true, And we stand with you in all you do, Together we will face this fight, with hope and love, shining bright. So when you feel like giving in, Remember, we are here to win, And though the road may be rough and steep, We’ll hold your hand and never let you weep. For you are not just a cancer patient, But a warrior, a hero, a testament, To the strength of the human spirit, And we’ll stand by you, every minute. So rest now, dear one, and know, That we’ll be with you as you go, Through the valleys and the peaks, with love, hope, and endless streaks. I am fearful, I am anxious, and I may not sleep, but the faith in my fight will never take a leap Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"88 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135698946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABSTRACT Probiotics modulate immune responses, enhance anti-tumoral immune surveillance, promote apoptosis of cancer cells, suppress tumor progression by their cytotoxic activity, and target the epigenetic changes in the cancer cell population. Evidence from the literature suggests that the role of probiotics in oral carcinogenesis is limited as compared to that in colon and gastric cancer. The present review aims to describe the immune modulation by probiotics in deterring carcinogenesis with an emphasis on oral cancer. We searched for relevant articles (in vitro and animal studies) published between January 2011 and December 2022 in PubMed, Scopus, and Google Scholar, both by electronic and manual means with the medical subject headings (MeSH) terms: “probiotics,” “carcinogenesis,” “immune modulation,” and “oral cancer.” The identified studies were analyzed by two independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eight articles met the requirements and were included. The data suggested that probiotics had immunomodulatory and anti-tumorigenic effects. Clinical studies are required to encourage the assessment of probiotics to inhibit tumor cell proliferation, prevent metastasis, and support anti-cancer therapy.
{"title":"Immune modulation by probiotics in deterring carcinogenesis with an emphasis on oral cancer: A narrative review","authors":"V Vasanthi, Kavitha Sanjeev, Krishnan Rajkumar, Bose Divya, Annasamy Rameshkumar, Shanti Swarup, Ramya Ramadoss","doi":"10.4103/crst.crst_361_22","DOIUrl":"https://doi.org/10.4103/crst.crst_361_22","url":null,"abstract":"ABSTRACT Probiotics modulate immune responses, enhance anti-tumoral immune surveillance, promote apoptosis of cancer cells, suppress tumor progression by their cytotoxic activity, and target the epigenetic changes in the cancer cell population. Evidence from the literature suggests that the role of probiotics in oral carcinogenesis is limited as compared to that in colon and gastric cancer. The present review aims to describe the immune modulation by probiotics in deterring carcinogenesis with an emphasis on oral cancer. We searched for relevant articles (in vitro and animal studies) published between January 2011 and December 2022 in PubMed, Scopus, and Google Scholar, both by electronic and manual means with the medical subject headings (MeSH) terms: “probiotics,” “carcinogenesis,” “immune modulation,” and “oral cancer.” The identified studies were analyzed by two independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eight articles met the requirements and were included. The data suggested that probiotics had immunomodulatory and anti-tumorigenic effects. Clinical studies are required to encourage the assessment of probiotics to inhibit tumor cell proliferation, prevent metastasis, and support anti-cancer therapy.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135699262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/crst.crst_168_23
N Aravind, Nizamudheen M. Pareekutty, Satheesan Balasubramanian, Akhil P. Suresh, Ratheesan Kumbakara
ABSTRACT Export Background: Total mesorectal excision (TME), which is the mainstay of the surgical management of carcinoma rectum, can either be achieved by open or laparoscopic techniques. Short-term benefits of laparoscopy were confirmed in previous meta-analyses, which found no difference in overall and disease-free survival, but data on pathologic outcomes of laparoscopy versus open surgery are heterogeneous. Objectives: The objective was to compare the pathological outcomes of laparoscopic with open rectal cancer resection. Materials and Methods: The LapPath (laparoscopic–pathological) study was a retrospective observational study conducted on patients with rectal cancers who underwent surgery between November 2017 and April 2020 at the Malabar Cancer Center, a tertiary cancer hospital in Thalassery, Kannur district in Kerala, South India. We divided the cohort based on whether the patients underwent laparoscopic or open surgery and compared various pathological outcomes in the two groups, including the quality of TME, nodal count, distal, and proximal margins. Results: We enrolled 170 patients, 98 (57%) had undergone laparoscopy and 72 (41.9%) had undergone open surgery. TME was complete in 68 (69.3%), near-complete in 30 (31%), and incomplete in 0 patients who underwent laparoscopic resection, versus 52 (72.2%), 20 (27.8%), and 0 patients who underwent open surgery; P, 0.554. The mean proximal margin was 11.1 cm (standard deviation [SD], 4.9) in the laparoscopic compared to 8.9 cm (SD, 6.5) in the open cohort; P, 0.434. The mean distal margin was 4.3 cm (SD, 2) in the laparoscopic group and 8 cm (SD, 6.6) in the open surgical group; P, 0.036. There were no cases in either group in which the proximal or distal margins were involved. The mean nodal count was also similar between the two groups: 10 (SD, 9.4) in the laparoscopic resection cohort and 9 (SD, 7.5) in the open surgery cohort; P, 0.475. Conclusions: Laparoscopic rectal cancer surgery leads to similar pathological outcomes as open surgery. This study contributes to the evidence for oncologic safety of laparoscopic rectal cancer resections in patients with disease staged up to T3.
摘要输出背景:直肠全系膜切除术(TME)是直肠癌外科治疗的主要方法，可通过开放或腹腔镜技术实现。先前的荟萃分析证实了腹腔镜手术的短期益处，发现总生存率和无病生存率没有差异，但腹腔镜手术与开放手术的病理结果数据存在差异。目的:比较腹腔镜下与开放式直肠癌切除术的病理结果。材料和方法:LapPath(腹腔镜-病理)研究是一项回顾性观察性研究，对2017年11月至2020年4月在印度南部喀拉拉邦坎努尔区Thalassery的三级癌症医院Malabar癌症中心接受手术的直肠癌患者进行了研究。我们根据患者是否接受腹腔镜或开放手术来划分队列，并比较两组的各种病理结果，包括TME质量、淋巴结计数、远端和近端边缘。结果:我们纳入170例患者，其中98例(57%)行腹腔镜手术，72例(41.9%)行开放手术。腹腔镜切除术患者TME完全68例(69.3%)，接近完全30例(31%)，不完全0例，开放手术患者52例(72.2%)，20例(27.8%)和0例;0.554 P。腹腔镜组的平均近端切缘为11.1 cm(标准差[SD]， 4.9)，而开放组的平均近端切缘为8.9 cm (SD, 6.5);0.434 P。腹腔镜组远端切缘平均为4.3 cm (SD, 2)，开放手术组平均为8 cm (SD, 6.6);0.036 P。两组均无近端或远端边缘受累的病例。两组的平均淋巴结数也相似:腹腔镜切除组为10个(SD, 9.4)，开放手术组为9个(SD, 7.5);0.475 P。结论:腹腔镜直肠癌手术的病理结果与开放手术相似。本研究为分期至T3期的腹腔镜直肠癌切除术的肿瘤学安全性提供了证据。
{"title":"The LapPath study: Comparison of pathologic outcomes of laparoscopic versus open rectal cancer surgery—A retrospective analysis from a tertiary cancer center in South India","authors":"N Aravind, Nizamudheen M. Pareekutty, Satheesan Balasubramanian, Akhil P. Suresh, Ratheesan Kumbakara","doi":"10.4103/crst.crst_168_23","DOIUrl":"https://doi.org/10.4103/crst.crst_168_23","url":null,"abstract":"ABSTRACT Export Background: Total mesorectal excision (TME), which is the mainstay of the surgical management of carcinoma rectum, can either be achieved by open or laparoscopic techniques. Short-term benefits of laparoscopy were confirmed in previous meta-analyses, which found no difference in overall and disease-free survival, but data on pathologic outcomes of laparoscopy versus open surgery are heterogeneous. Objectives: The objective was to compare the pathological outcomes of laparoscopic with open rectal cancer resection. Materials and Methods: The LapPath (laparoscopic–pathological) study was a retrospective observational study conducted on patients with rectal cancers who underwent surgery between November 2017 and April 2020 at the Malabar Cancer Center, a tertiary cancer hospital in Thalassery, Kannur district in Kerala, South India. We divided the cohort based on whether the patients underwent laparoscopic or open surgery and compared various pathological outcomes in the two groups, including the quality of TME, nodal count, distal, and proximal margins. Results: We enrolled 170 patients, 98 (57%) had undergone laparoscopy and 72 (41.9%) had undergone open surgery. TME was complete in 68 (69.3%), near-complete in 30 (31%), and incomplete in 0 patients who underwent laparoscopic resection, versus 52 (72.2%), 20 (27.8%), and 0 patients who underwent open surgery; P, 0.554. The mean proximal margin was 11.1 cm (standard deviation [SD], 4.9) in the laparoscopic compared to 8.9 cm (SD, 6.5) in the open cohort; P, 0.434. The mean distal margin was 4.3 cm (SD, 2) in the laparoscopic group and 8 cm (SD, 6.6) in the open surgical group; P, 0.036. There were no cases in either group in which the proximal or distal margins were involved. The mean nodal count was also similar between the two groups: 10 (SD, 9.4) in the laparoscopic resection cohort and 9 (SD, 7.5) in the open surgery cohort; P, 0.475. Conclusions: Laparoscopic rectal cancer surgery leads to similar pathological outcomes as open surgery. This study contributes to the evidence for oncologic safety of laparoscopic rectal cancer resections in patients with disease staged up to T3.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135700459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bendamustine: An old drug for a potential new indication!","authors":"Sudhir Kirar, O. Suri, L. Kumar","doi":"10.4103/crst.crst_60_23","DOIUrl":"https://doi.org/10.4103/crst.crst_60_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"7 1","pages":"156 - 158"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79824109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：